Akorn Inc. buy melinda
Start price
17.11.18
/
50%
€6.16
Target price
22.01.19
€7.22
Performance (%)
-44.88%
End price
22.01.19
€3.40
Summary
This prediction ended on 22.01.19 with a price of €3.40. The BUY prediction by melinda for Akorn Inc. performed very badly with a performance of -44.88%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Akorn Inc. | - | - | - | - |
| iShares Core DAX® | 0.597% | 3.083% | 16.090% | 16.439% |
| iShares Nasdaq 100 | 0.899% | 5.338% | 29.239% | 56.431% |
| iShares Nikkei 225® | 1.775% | -1.206% | 6.823% | 4.774% |
| iShares S&P 500 | 0.990% | 3.500% | 24.956% | 47.182% |
Comments by melinda for this prediction
In the thread Akorn Inc. diskutieren
SecteurProduits pharmaceutiques Agenda 27/02 Publication de résultats
Akorn, Inc. operates as a niche pharmaceutical company that develops, manufactures and markets generic and prescription pharmaceuticals, as well as, animal and consumer health products.
It operates through the Prescription Pharmaceuticals and Consumer Health segments.
The Prescription Pharmaceuticals segment engages in the sales of generic and branded prescription pharmaceuticals including ophthalmics, injectables, oral liquids, otics, topicals, inhalants, and nasal sprays.
The Consumer Health segment engages in the sales of animal health and over-the-counter products, both branded and private label.
The company was founded in 1971 and is headquartered in Lake Forest, IL.
Nombre d'employés : 2 308 personnes.
(Vom Mitglied beendet)